熱門資訊> 正文
Protalix BioTherapeutics第二季度盈利预览
2025-08-14 01:11
- Protalix BioTherapeutics (NYSE:PLX) is scheduled to announce Q2 earnings results on Thursday, August 14th, before market open.
- The consensus EPS Estimate is $0.03 and the consensus Revenue Estimate is $13.49M (+0.1% Y/Y).
- Over the last 1 year, PLX has beaten EPS estimates 50% of the time and has beaten revenue estimates 100% of the time.
More on Protalix BioTherapeutics
- Protalix BioTherapeutics appoints Gilad Mamlok as CFO
- Seeking Alpha’s Quant Rating on Protalix BioTherapeutics
- Historical earnings data for Protalix BioTherapeutics
- Financial information for Protalix BioTherapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
